Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07582172CT.gov Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | — | Not Yet Recruiting | — | — | — |
NCT06954987CT.gov Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | — | Not Yet Recruiting | — | — | — |
NCT07012044CT.gov A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05565105CT.gov CD34+ Transplants for Leukemia and Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07642453CT.gov VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | — | Not Yet Recruiting | — | — | — |
NCT06996119CT.gov Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant | — | Recruiting | — | — | — |
NCT07514832CT.gov VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | — | Recruiting | — | — | — |
NCT06930352CT.gov Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | — | Not Yet Recruiting | — | — | — |
NCT07507760CT.gov Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | — | Not Yet Recruiting | — | — | — |
NCT07507825CT.gov Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) | — | Not Yet Recruiting | — | — | — |
Show 189 more trialsShow fewer
NCT07651475CT.gov Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | — | Active Not Recruiting | — | — | — |
NCT06871410CT.gov Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06928662CT.gov Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | — | Recruiting | — | — | — |
NCT07044544CT.gov Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | — | Recruiting | — | — | — |
NCT06287944CT.gov 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT06815003CT.gov Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | — | Recruiting | — | — | — |
NCT06763666CT.gov CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML | — | Not Yet Recruiting | — | — | — |
NCT06660368CT.gov BCL2i CLAG-M in R/R Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06158828CT.gov Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML | — | Recruiting | — | — | — |
NCT06741722CT.gov Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | — | Recruiting | — | — | — |
NCT06613035CT.gov Twice-per-weekSelinexor, 2 Days Melphalan | — | Not Yet Recruiting | — | — | — |
NCT06007911CT.gov Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT06059391CT.gov CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | — | Recruiting | — | — | — |
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
NCT06195891CT.gov Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT06387069CT.gov A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06928376CT.gov A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | — | Recruiting | — | — | — |
NCT06316960CT.gov Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | — | Recruiting | — | — | — |
NCT06001788CT.gov Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06394011CT.gov Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | — | Recruiting | — | — | — |
NCT07437170CT.gov Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | — | Active Not Recruiting | — | — | — |
NCT06034470CT.gov Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT06001385CT.gov HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | — | Active Not Recruiting | — | — | — |
NCT06084819CT.gov Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05875649CT.gov A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure | — | Not Yet Recruiting | — | — | — |
NCT04354025CT.gov Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | — | Withdrawn | — | — | — |
NCT05735717CT.gov MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | — | Recruiting | — | — | — |
NCT05805072CT.gov Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05317403CT.gov Venetoclax to Augment Epigenetic Modification and Chemotherapy | — | Recruiting | — | — | — |
NCT05457556CT.gov Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | — | Active Not Recruiting | — | — | — |
NCT06068621CT.gov Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05330377CT.gov GM-CLAG in Relapsed/Refractory FLT3-mutated AML | — | Withdrawn | — | — | — |
NCT05918198CT.gov Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05726110CT.gov Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05659992CT.gov Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05603884CT.gov VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05662956CT.gov A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | — | Completed | — | — | — |
NCT04282174CT.gov CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies | — | Withdrawn | — | — | — |
NCT05170828CT.gov Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | — | Withdrawn | — | — | — |
NCT05599360CT.gov Vyxeos for Induction of Low- or Intermediate-risk. | — | Active Not Recruiting | — | — | — |
NCT05139004CT.gov 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | — | Active Not Recruiting | — | — | — |
NCT04982354CT.gov Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT05115630CT.gov Off-the-shelf NK Cells + SCT for Myeloid Malignancies | — | Completed | — | — | — |
NCT04849910CT.gov Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | — | Terminated | — | — | — |
NCT04898894CT.gov Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04904588CT.gov HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | — | Active Not Recruiting | — | — | — |
NCT05029141CT.gov New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04872595CT.gov A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | — | Active Not Recruiting | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04824794CT.gov GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | — | Terminated | — | — | — |
NCT04824924CT.gov A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy | — | Unknown | — | — | — |
NCT04254640CT.gov Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | — | Unknown | — | — | — |
NCT04195633CT.gov Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | — | Recruiting | — | — | — |
NCT04678401CT.gov IS-free Treg HaploHCT | — | Recruiting | — | — | — |
NCT04250051CT.gov Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04375631CT.gov CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | — | Recruiting | — | — | — |
NCT04599452CT.gov NK Cell Therapy Recurrent/Refractory Elderly AML | — | Unknown | — | — | — |
NCT04614636CT.gov FT538 in Subjects With Advanced Hematologic Malignancies | — | Terminated | — | — | — |
NCT04240002CT.gov A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT04473911CT.gov Haplo Peripheral Blood Sct In GVHD Prevention | — | Completed | — | — | — |
NCT04002115CT.gov Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | — | Terminated | — | — | — |
NCT04216771CT.gov Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | — | Unknown | — | — | — |
NCT05982756CT.gov Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML | — | Unknown | — | — | — |
NCT04050280CT.gov CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | — | Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03860844CT.gov Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04087967CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | — | Unknown | — | — | — |
NCT04083911CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | — | Unknown | — | — | — |
NCT03849651CT.gov TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT03674411CT.gov Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | — | Active Not Recruiting | — | — | — |
NCT03504410CT.gov Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML | — | Terminated | — | — | — |
NCT03665480CT.gov The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | — | Unknown | — | — | — |
NCT03250338CT.gov Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | — | Completed | — | — | — |
NCT03615105CT.gov Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | — | Terminated | — | — | — |
NCT03661515CT.gov Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | — | Completed | — | — | — |
NCT03441048CT.gov Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03600909CT.gov A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | — | Terminated | — | — | — |
NCT03480360CT.gov Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | — | Active Not Recruiting | — | — | — |
NCT03434730CT.gov Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | — | Completed | — | — | — |
NCT03985007CT.gov CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03182244CT.gov A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | — | Active Not Recruiting | — | — | — |
NCT03096782CT.gov Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | — | Completed | — | — | — |
NCT03214562CT.gov Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03247088CT.gov Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT03263936CT.gov Epigenetic Reprogramming in Relapse/Refractory AML | — | Completed | — | — | — |
NCT03356080CT.gov DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | — | Unknown | — | — | — |
NCT03164057CT.gov A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03150004CT.gov Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | — | Terminated | — | — | — |
NCT02791919CT.gov Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT02809092CT.gov Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02782546CT.gov Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT03045627CT.gov Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | — | Unknown | — | — | — |
NCT03012672CT.gov Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | — | Completed | — | — | — |
NCT02793544CT.gov HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | — | Completed | — | — | — |
NCT02728050CT.gov Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02921061CT.gov Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | — | Completed | — | — | — |
NCT02771197CT.gov Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | — | Completed | — | — | — |
NCT02933333CT.gov G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | — | Unknown | — | — | — |
NCT02756572CT.gov Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | — | Completed | — | — | — |
NCT02807558CT.gov A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02790515CT.gov Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | — | Active Not Recruiting | — | — | — |
NCT02750254CT.gov Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | — | Terminated | — | — | — |
NCT02886559CT.gov Chidamide Plus DCAG for Relapsed/Refractory AML | — | Unknown | — | — | — |
NCT02727803CT.gov Personalized NK Cell Therapy in CBT | — | Recruiting | — | — | — |
NCT02626338CT.gov Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | — | Completed | — | — | — |
NCT03181815CT.gov Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02593123CT.gov Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | — | Completed | — | — | — |
NCT02614560CT.gov A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients | — | Terminated | — | — | — |
NCT02528877CT.gov Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | — | Withdrawn | — | — | — |
NCT02421939CT.gov A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | — | Completed | — | — | — |
NCT02400281CT.gov Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | — | Completed | — | — | — |
NCT02416908CT.gov Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02432911CT.gov Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old | — | Unknown | — | — | — |
NCT02427919CT.gov Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML | — | Unknown | — | — | — |
NCT02412475CT.gov Epigenetic Reprogramming in Relapse AML | — | Terminated | — | — | — |
NCT02240537CT.gov Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer | — | Unknown | — | — | — |
NCT02416388CT.gov Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | — | Recruiting | — | — | — |
NCT02275663CT.gov Azacytidine Plus FLAG for Relapsed or Refractory AML | — | Unknown | — | — | — |
NCT02282215CT.gov Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02319135CT.gov Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02259348CT.gov Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | — | Terminated | — | — | — |
NCT01787474CT.gov Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01904136CT.gov Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT02143830CT.gov HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | — | Recruiting | — | — | — |
NCT02171117CT.gov Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02088541CT.gov Selinexor (KPT-330) in Older Patients With Relapsed AML | — | Completed | — | — | — |
NCT01885689CT.gov Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02072811CT.gov Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02105116CT.gov AML Therapy With Irradiated Allogeneic Cells | — | Terminated | — | — | — |
NCT02044796CT.gov Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT01700673CT.gov Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | — | Completed | — | — | — |
NCT01619761CT.gov NK Cells in Cord Blood Transplantation | — | Unknown | — | — | — |
NCT01685411CT.gov Busulfan and Cyclophosphamide Followed By ALLO BMT | — | Terminated | — | — | — |
NCT01701323CT.gov Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03393611CT.gov CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01745913CT.gov Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | — | Terminated | — | — | — |
NCT01435343CT.gov Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | — | Completed | — | — | — |
NCT01572662CT.gov Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | — | Completed | — | — | — |
NCT04687098CT.gov Risk-adapted Therapy for Primary Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01455025CT.gov Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01408563CT.gov Reduced Intensity Double Umbilical Cord Blood Transplantation | — | Completed | — | — | — |
NCT01478074CT.gov ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT01500161CT.gov Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | — | Terminated | — | — | — |
NCT01484171CT.gov HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT01158118CT.gov Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | — | Completed | — | — | — |
NCT01297543CT.gov Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | — | Completed | — | — | — |
NCT00906945CT.gov Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01161550CT.gov Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | — | Completed | — | — | — |
NCT00943943CT.gov Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | — | Completed | — | — | — |
NCT01076270CT.gov Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | — | Terminated | — | — | — |
NCT01119066CT.gov HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT01031368CT.gov Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01698879CT.gov Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment | — | Completed | — | — | — |
NCT00916045CT.gov Pilot Study of Unrelated Cord Blood Transplantation | — | Terminated | — | — | — |
NCT00939653CT.gov T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
NCT01050764CT.gov Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | — | Terminated | — | — | — |
NCT00932412CT.gov The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial) | — | Completed | — | — | — |
NCT00863434CT.gov Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | — | Terminated | — | — | — |
NCT00864227CT.gov Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | — | Completed | — | — | — |
NCT00849147CT.gov Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | — | Completed | — | — | — |
NCT00566696CT.gov Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | — | Completed | — | — | — |
NCT00602225CT.gov Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00594555CT.gov A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT00462605CT.gov MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00469014CT.gov Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00536601CT.gov High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT02182596CT.gov DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML | — | Completed | — | — | — |
NCT02831192CT.gov Microtransplantation in Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00363467CT.gov Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation | — | Terminated | — | — | — |
NCT00789256CT.gov Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | — | Completed | — | — | — |
NCT01723657CT.gov Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00195000CT.gov Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | — | Completed | — | — | — |
NCT00067002CT.gov Randomized Double Cord Blood Transplant Study | — | Completed | — | — | — |
NCT00516152CT.gov Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | — | Completed | — | — | — |
NCT01020539CT.gov Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | — | Completed | — | — | — |
NCT00304447CT.gov Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia | — | Completed | — | — | — |
NCT00683046CT.gov T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT00161668CT.gov Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care | — | Completed | — | — | — |
NCT00038831CT.gov Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | — | Completed | — | — | — |
NCT00012376CT.gov Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | — | Completed | — | — | — |
NCT00571662CT.gov Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | — | Completed | — | — | — |
NCT00176839CT.gov Stem Cell Transplantation for Hematological Malignancies | — | Terminated | — | — | — |
NCT00199147CT.gov Efficacy of G-CSF-Priming in Elderly AML Patients | — | Unknown | — | — | — |
NCT00004918CT.gov Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00636909CT.gov Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | — | Completed | — | — | — |
NCT00266136CT.gov Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | — | Completed | — | — | — |
NCT00209833CT.gov Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | — | Unknown | — | — | — |
NCT00487448CT.gov SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | — | Completed | — | — | — |
NCT00820976CT.gov Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | City of Hope Medical Center | Approved | BB · 67 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-acute-myeloid-leukemia-1593
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →